recent advancement in managing diabetic nephropathy
TRANSCRIPT
RECENT ADVANCES IN
MANAGING AND UNDERSTANDING
DIABETIC NEPHROPATHY
Presented by :
Mr. Prashant Shivgunde
Assistant Professor,
University Department of Interdisciplinary Research and Technology,
Maharashtra University Health Sciences, Nashik1/25/2017
Contents
• Introduction
• Pathophysiology of Diabetic Nephropathy
• Current Standard of Approach to Diabetic Nephropathy
• Novel Therapeutic Modalities
• Some of the Newer Drugs and Terminated RCTs 1/25/2017
2
Diabetes Mellitus
• Prevalence of diabetes mellitus (DM) is 8.5% and increasing
• Most affected with Type 2 DM• Epidemic for several decades • Associated with many complications
• Diabetic kidney disease (DKD) is a leading complication of diabetes, which can lead to serious consequences, including kidney failure and cardiovascular morbidity and mortality
1/25/2017
4
Chronic Kidney Disease
• 8% to 16% prevalence of CKD globally and is steadily rising
• QOL
• Medical expenses are costly
1/25/2017
5
CKD prognosis example
100%
Patients
Stage 3 CKD 1/25/2017
6
27%
8%65%
Patients
Stage 3 CKD RRT Dead Patients
After 10 Years
CKD and Diabetes
• As a cause of ESRD, diabetic nephropathy (DN) ranks first
• DN is clinically characterized by • Proteinuria (mostly albuminuria), • Elevated serum creatinine levels, and • Decreased eGFR
• More than 20% of patients starting dialysis are dead within the first year and more than 70% of diabetic patients starting dialysis are dead within 5 years
1/25/2017
7
Percentage of diabetic patients who are likely to progress through each stage
1/25/2017
8
Normal albumin excretion
Persistent MicroalbuminuriaMicroalbuminuria
Proteinuria
Renal Failure
20-30%~50% (2-4% per annum)
40%
30%
Raising blood pressure and cardiovascular disease risk
Table 1: Likelihood of DKD based on UACR and GFR
1/25/2017
9
Albuminuria
GFR* CKD Stage† None‡ UACR 30-299 mg/g UACR ≥300 mg/g
>60 1+2 At risk Possible DKD DKD
30–60 3 Unlikely DKD Possible DKD DKD
<30 4+5 Unlikely DKD Unlikely DKD DKD
*GFR expressed in mL/min.†The NKF recommends using albuminuria data before initiation of RAAS inhibitor therapy to determine the
staging.‡UACR <30 mg/g
Diabetic Nephropathy
• Affects approx. one-third of individuals with diabetes mellitus
• NHANES program during 1988–2008
• Prevalence of DKD increased (2.2%–3.3%) in proportion to the prevalence
of diabetes (6.0%–9.4%)
• The excess mortality risk of DM is practically exclusively
correlated with the occurrence of DN
1/25/2017
10
Diabetic Nephropathy
• Burden of ESRD from type 2 diabetes mellitus(T2DM) is expected to burgeon by four fold
• Why some diabetic patients develop nephropathy whereas others do not- ?
• DN pathogenesis remains obscure
1/25/2017
11
Drug Development
• Fewer interventional trials to develop therapeutics
• Obstacles are• Slow patient enrolment (in part because of a lack of disease awareness), • Regulatory requirements for hard patient outcomes for drug
registration, and • Lack of payer engagement
• Only unmet medical need attract some pharmaceutical companies.
1/25/2017
12
Pathogenetic Mechanisms
• Heavy inflammatory element triggered by metabolic disorders,
protein overload, and hemodynamic abnormalities
• Traditionally, Glomerular in origin
• Emerging data suggest that the tubular epithelial cell
1/25/2017
14
Effects of - High Glucose
1/25/2017
15
IncreasesNADH:NAD
Ratio
High Glucose
Aldose ReductasePathway
DAG synthesis
PKC
ROS
AGE
RAGE
1/25/2017
16Free Amino Groups (Proteins , Lipids, & Nucleic Acids
Reducing Sugar
Under High Glucose
Ambience
Non-Enzymatic Interaction
Labile Schiff Base
Amadori Rearrangement
Dehydration
Polymerization
AGE’s
ROS
Interact With
RAGE and Other Binding Protein
(OST-48, 80 K-H, Galectin)
Induce Various Intracellular
Events
Activate PKC, MAP Kinase and Transcription factor
such as NF-κβ
Increased synthesis of Type I & IV Collagens
Activate Transcription factor such as TGF-β and alter expression of ECM
proteins
Decreased Expression Of Proteoglycans
Anomalous ECM polymerization and
expansion
Covalently Bind With Proteins Thus Compounding With Various Deleterious Effect in Tissues
17
18Membrane Barrier
High Glucose and Ang II-induced JAK/STAT pathway in kidney mesangial cell growth
O2
NADPH oxidase
Angiotensin II
AT1
High Glucose
Polyol Pathway
RAGE
PKC-beta
AGE
PLD2
JAK2 and STATs
SHP-1 and SHP-2
PLC-gamma1
DAG
AldoseReductase
The Triumvirate
• Intensive control of Blood Glucose
• Intensive control of Blood Pressure
• RAAS Blockade
1/25/2017
20
Glycaemic Optimization
• Study - EDIC (Epidemiology of Diabetes Interventions and Complications- Cohort)
• Type 1 diabetics clearly demonstrated a legacy effect of early intensive diabetic control-• 44% reduction in developing CKD with eGFR lower than 60 ml/min/1.73m2
1/25/2017
22
Glycaemic Optimization
• Study- UK Prospective Diabetes Study (UKPDS)
• 3,867 Patients (newly diagnosed)
• Conventional Group HbA1c 7.9%
• For type 2 diabetics the risk in the intensive group was • 12% lower for any diabetes-related endpoint; • 10% lower for any diabetes-related death; and • 6% lower for all-cause mortality
1/25/2017
23
Glycaemic Optimization
• Study- ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation) trial
• 11,140 patients
• Demonstrated the value of tight glycaemic control• Reduction of albuminuria (9% and 30% for micro- and macro-albuminuria,
respectively) and 65% risk reduction of ESRD
1/25/2017
24
Glycaemic Optimization
• Encouraging data must be interpreted with caution
• UKPDS, patients in the intensive group had significantly more hypoglycaemic episodes
• Study - ACCORD (Action to Control Cardiovascular Risk in Diabetes)• Terminated early due to excess mortality in the intensive therapy arm
(HbA1c target <6.0%) versus the standard arm (HbA1c 7.0–7.9%)
1/25/2017
25
Glycaemic Optimization
• What constitutes optimal diabetic control?
1/25/2017
26
Aim- to strike a balance between the risk of hypoglycaemia and the clear benefit of reno-protection
The American Association of Clinical Endocrinologists
Target of HbA1c <6.5%
American Diabetes Association
Target of HbA1c <7%
Glycaemic Optimization
• The Steno-2 study (microalbuminuria)-
• Target-driven, long-term, intensified intervention aimed at multiple risk factors• Blood pressure < 130/80 mmHg, • Proteinuria < 0.3 g/day, • Low density lipoprotein [LDL] < 100 mg/dL, • ldl + very low density lipoprotein < 130 mg/dL, • HbA1c < 7.0%, smoking cessation, and • Near normalization of anemia of hemoglobin of 11 to 13 g/dL
1/25/2017
27
Glycaemic Optimization
• Reduced the risks of cardiovascular and microvascular events, by approximately 50%
• In elderly, stricter established target levels • hypoglycaemia and cerebrovascular ischemic events chances
• Thus, treatment targets should be tailored
1/25/2017
28
Glycaemic Vs Blood Pressure Control
• Depends on the clinical circumstances of the individual
1/25/2017
29
Significance
Glycaemic control
Normoalbuminuria to microalbuminuria progression
Blood pressure control
Once microalbuminuria has shifted into a macroalbu-
minuric state
Blood Pressure Control
• Hypertension an independent, modifiable variable • Predisposes individuals to the development and acceleration of micro- and
macro-vascular problems• Various attempts to optimize RAAS inactivation
• Several trials have been conducted to validate the efficacy• Angiotensin converting enzyme inhibitors (ACEI) or Angiotensin II type 1
receptor blockers (ARBs) alone, • Combined use of ACEI and ARBs, • Renin inhibitors (aliskiren), • Aldosterone inhibitors (spironolactone or eplerenone), and • Angiotensin II type 2 receptor enhancement 1/25/2017
30
Blood Pressure Control
• UKPDS showed for every 10 mmHg reduction in SBP, there was a decrease in • All DM-related complications by 12%• Death by 15%
• Echoed in the RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) trial• 1,513 type 2 DM patients with confirmed DN and hypertension• Risk of ESRD or death was raised by 6.7% for each 10 mmHg increase in
baseline SBP
1/25/2017
31
Renin-angiotensin-aldosterone Axis Blockade
• Type 2 DM-• ACEi or ARB is superior to using other anti-hypertensive agents• Provide other renoprotective benefits, (MARVAL -Micro-Albuminuria
Reduction with Valsartan study)
• Type 1 DM –• Study- meta-analysis of 698 non-hypertensive type 1 DM patients with
micro-albuminuria• Treatment with ACEi restricted development to macro-albuminuria by
60%
1/25/2017
32
Renin-angiotensin-aldosterone Axis Blockade
• Sub-study of the IRMA-2 (Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria) trial • Reduction in micro-albuminuria by RAS blockade persisted even after
treatment withdrawal
• IDNT (Irbesartan Diabetic Nephropathy Trial)• 1,715 hypertensive type 2 DN patients • 33% decrease in the risk of serum creatinine doubling• 23% decrease in progression to ESRD
1/25/2017
33
Renin-angiotensin-aldosterone Axis Blockade
• Similar observations of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan)• 50% decrease in albuminuria after 6 months of losartan treatment
correlated with a 45% decreased risk for ESRD
• Findings recapitulate the renoprotective effect of captopril in type 1 diabetics with overt nephropathy
1/25/2017
34
1/25/2017
35
Drug Trial Notes
Valsartan MARVAL
(Micro-Albuminuria Reduction with
Valsartan)
Reduction in BP +
micro-albuminuria
Irbesartan IRMA-2
(Irbesartan in Patients with Type 2
Diabetes and Microalbuminuria)
Reduction in micro-albuminuria
persisted, even after treatment withdrawal,
implies that glomerular structural normalization
may be occurring
Irbesartan IDNT
(Irbesartan Diabetic Nephropathy
Trial)
GFR decline,
33% and 23% Risk reduction of serum creatinine
doubling and progression to ESRD respectively
losartan RENAAL
RENAAL (Reduction of Endpoints in
NIDDM with the Angiotensin II
Antagonist Losartan)
GFR decline,
50% & 45% decrease in albuminuria & risk for
ESRD respectively after 6 months treatment
Renin-Angiotensin-Aldosterone Axis Blockade
• Comparison between ACEi and ARB • Appear to have comparable efficacy in DN, • Intractable dry cough may be associated with ACE inhibition
• Findings are reinforced by the DETAIL (Diabetics Exposed to Telmisartan and Enalapril) trial • RCT in 250 type 2 DN patients• No difference after 5 years- degree of GFR decline, albuminuria and
ESRD incidence
1/25/2017
36
Renin-Angiotensin-Aldosterone Axis Blockade
• Secondary prevention trials have so far provided all existing data for RAS blockade
• The NKF KDOQI clinical practice guidelines have not recommended using ACEi or ARB for the primary prevention of DN in normotensive individuals with normo-albuminuria
1/25/2017
37
Exploiting the Renin-Angiotensin-Aldosterone Axis
• Combining ACEi and ARB to maximize RAS blockade
• CALM (Candesartan and Lisinopril Micro-albuminuria) study• A combination of candesartan and lisinopril• Lowered micro-albuminuria more effectively than either drug alone at 12
weeks
• Longer follow-up studies were never able to reproduce these short-term results
1/25/2017
38
Exploiting the Renin-Angiotensin-Aldosterone Axis
• RCT—ONTARGET (Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial),
• Ramipril, telmisartan or both were administered to 25,620 high vascular risk patients (37.5% diabetics)
• Combination therapy was shown to increase the composite outcome of dialysis, doubling of serum creatinine and death
1/25/2017
39
Exploiting the Renin-Angiotensin-Aldosterone Axis
• VA NEPHRON-D (Veterans Affairs Nephropathy in Diabetes)
• 1,448 type 2 DN patients with eGFR 30–89.9 mL/min/1.73m2
• Treated with losartan alone or in combination with lisinopril• Trial ended early- no renal benefit and an excessive risk of hyperkalemia
(9.9% vs. 4.4%) and acute kidney injury (18% vs. 11%)
• In DN patients with more advanced CKD, dual RAS inhibition would carry an even greater risk
1/25/2017
40
Aldosterone Antagonism
• Mineralocorticoid receptor antagonist (MRA) • Meta-analyses have demonstrated that a supplement of MRA given to
those treated with ACEi or ARB produces a decrease in proteinuria
• Likewise beneficial effects observed in administration of non-selective and selective MRA
• But, Several studies, in combination with RAS inhibition showed• A greater risk of hyperkalemia
1/25/2017
41
Non-steroidal MRA Antagonism
• Finerenone• Increased receptor selectivity compared to spironolactone and • Greater receptor affinity than eplerenone in vitro, • A less frequent occurrence of hyperkalemia than spironolactone
• Finerenone added to ACEi or ARB• Produced a dose-dependent decrease in UACR without inducing
hyperkalemia at day 90• The study had several important limitations
1/25/2017
42
Lipid Lowering Therapy
• Statins are the most widely used class of drug for lipid lowering in individuals with type 2 diabetes• reflects the indisputable evidence
• The role of lipid-lowering treatments in renoprotection for patients with diabetes, however, is debatable.
• In the Heart Protection Study by MRC/BHF with subgroup analysis for participants with diabetes, allocation to simvastatin (40 mg/day)• Significantly decreased the rise in serum creatinine values• Limitation- Subjects with late stage CKD were not studied
1/25/2017
43
Lipid Lowering Therapy
• SHARP• comprising 23% diabetic subjects did not produce significant reductions
in any of the prespecified measures of renal disease progression among the subgroup of 6,247 nondialysis patients with a mean eGFR of 26.6 ml/min/1.73m2.
• Whether lipid lowering could only confer tangible renoprotection during early rather than late CKD requires further investigation
1/25/2017
44
Lipid Lowering Therapy
• GREACE study• Patients given atorvastatin had a significant reduction in urinary albumin
excretion; • However, separate analysis for type2 diabetes was not included in the study
• Findings echoed by the PLANET I study • Treatment with atorvastatin 80 mg lowered UPCR substantially more than
rosuvastatin 10 mg or rosuvastatin 40 mg
• It must be cautioned that such doses of atorvastatin are unusually high for the average CKD patient.
1/25/2017
45
Lipid Lowering Therapy
• Statins-
• Lowered mortality and cardiovascular events with early stages of CKD
• Little or no effects in those on dialysis
• Had uncertain effects in kidney transplant recipients
• Effects on stroke and kidney function remain to be elucidated
1/25/2017
46
Pleiotropic Renoprotective Effects of Anti-diabetic Drugs Beyond Glycaemic Control
PPAR-γ agonists
Incretin- based Agents
1/25/2017
48
PPAR-γ Agonists
• TZDs- Pioglitazone and Rosiglitazone
• Varied reports from clinical studies
• Heightened cardiovascular risks and malignancy
• TZDs are unlikely to be a major player in the therapeutic armamentarium for DN
1/25/2017
49
Incretin- Based Agents
• Incretins secreted into the circulation postprandially• Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like
peptide 1 (GLP-1) • Exert insulinotropic activity
• Impaired incretin regulation is implied in type 2 diabetes
• GLP-1 exerts antidiabetogenic properties by • stimulating insulin secretion, increasing β-cell mass, inhibiting glucagon
secretion, delaying gastric emptying and inducing satiety
1/25/2017
50
Incretin- Based Agents
• GLP-1gets rapidly degraded by dipeptidyl peptidase 4 (DPP-4)
• Limitation can be overcome by using • DPP-4 resistant GLP-1 receptor agonists and • DPP-4 inhibitors.
• Other than glycaemic effects reduce-• Blood pressure, • Dyslipidemia, and • Inflammation to a certain degree • Risk of hypoglycaemia
1/25/2017
51
Incretin- Based Agents
• Sitagliptin/ Alogliptin/ Saxagliptin
• Experimental models indicated renoprotective benefits
• Lowered albuminuria in patients with type 2 DM• 6 months of sitagliptin or 12 weeks of alogliptin• Data from small, uncontrolled studies
• Findings must be interpreted with caution
1/25/2017
52
Incretin- Based Agents
• Four phase III studies, comprising 217 patients with DN on RAS inhibition• 24 weeks of linagliptin significantly reduced albuminuria (32% reduction),
independent of HbA1c
• Advantages of DPP-4 inhibitors• Tolerability, • Weight neutral benefit and • Low risk of hypoglycaemia
1/25/2017
53
Incretin- Based Agents
• GLP 1 Agonists- Exenatide, liraglutide, dulaglutide
• Exenatide treatment in Type 2 DM• Reductions in both albuminuria and urinary levels of TGF-β and type IV
collagen
• The anti-fibrotic effect of linagliptin was demonstrated in a type 1 model of DN after 4 weeks of treatment
• Limited clinical evidence of the effect of targeting TGF-β
1/25/2017
54
Vitamin D Receptor Activators
• Anti-inflammatory and anti-proteinuric effects in animal models of DN
• Phase III VITAL trial in Patients with Type 2 Diabetes• Adjuvant paricalcitol at 2 μg/day lowers residual albuminuria in DN• Drawbacks-
• Poor tolerance- 42% of patients needed a reduced dose of paricalcitol,• High cost of treatment
• Concrete evidence demonstrating the successful use of VDR activators to retard the progression of DN is still awaited
1/25/2017
55
Sodium-Glucose Co-transporter 2 Inhibition
• Along with aiding glycemic control, SGLT-2 inhibitors appear to promote an attractive cardiovascular portfolio
• EMPA-REG study,Empagliflozin added to standard care• Over 7,000 type 2 diabetics at high cardiovascular risk• Reduced the rates of
• Death from cardiovascular causes (3.7%, vs. 5.9% in the placebo group; 38% RRR),
• Hospitalization for heart failure (2.7% Vs 4.1%, 35% RRR), and • Death from any cause (5.7% Vs 8.3%, 32% RRR)
1/25/2017
56
Sodium-Glucose Co-transporter 2 Inhibition
• Renoprotective effect of SGLT2 inhibitors attributed to a decrease in high glucose-induced inflammatory and fibrotic markers in human proximal tubular cells
• By blocking glucose entry into the cell empagliflozin attenuated High glucose-induced-• Expression of Toll-like receptor-4, binding of nuclear deoxyribonucleic
acid to nuclear factor κB and activator protein 1, and secretion of collagen IV and interleukin-6
1/25/2017
57
Sodium-Glucose Co-transporter 2 Inhibition
• Reporting with negligible clinical impact-• Drug dose-dependent hyperkalemia and urogenital infections
• Dapagliflozin in the most recent trial involving diabetic patients with moderately decreased renal function group showed favorable results in terms of reduced albuminuria
1/25/2017
58
Selective C-C Chemokine Receptor Type 2 Antagonism
• MCP-1 overexpression plays an indispensable role in promoting monocyte and macrophage migration and activation
• CCR2 antagonist- CCX140-B is a small molecule • Inhibits CCR2 and blocks MCP-1-dependent monocyte activation and
chemotaxis• Improved glycaemia and albuminuria in animal models
1/25/2017
59
Selective C-C Chemokine Receptor Type 2 Antagonism
• The first evidence that CCR2 inhibition lowers albuminuria in DN came from a recent European study
• Patients with type 2 DM, Age: 18–75 years with UACR 100–3000 mg/g, eGFR ≥25 mL/min/1.73m2, and taking stable antidiabetic treatment and an ACEi or ARB for at least 8 weeks
• Stratified to once a day• Oral placebo, • 5 mg CCX140-B, or • 10 mg CCX140-B
1/25/2017
60
Selective C-C Chemokine Receptor Type 2 Antagonism
• UACR changes (during 52 weeks)• -2% for placebo (95% CI -11% to 9%), • -18% for 5 mg CCX140-B (-26% to -8%), and • -11% for 10 mg CCX140-B (-20% to -1%)
• No significant difference in adverse events or renal events during the study.
1/25/2017
61
5’ Adenosine Monophosphate-activated Protein Kinase Activators
• AMPK is a metabolic master switch that regulates downstream signals based on shifts in surrounding energy reservoirs
• Evidence of dysregulation of AMPK in relevant tissues is implicated in the development of metabolic syndrome and diabetes
• Insulin-resistant animal models• AMPK activation proven to improve glucose and lipid homeostasis
coordinating anabolic processes
1/25/2017
62
5’ Adenosine Monophosphate-activated Protein Kinase Activators
• Metabolic stress –• Adenosine triphosphate (ATP) consumption -increase in the adenosine
monophosphate (AMP)/ATP ratio
• Several upstream kinases or compound molecule that consists of three proteins: • STE-related adaptor (STRAD), mouse protein 25 (MO25), and the tumor-
suppressor liver kinase B1 (LKB1)
• Upstream enzymes • Ca2+/calmodulin-dependent protein kinase kinase β (CaMKKβ) and • TGF β-activated kinase (TAK1) 1/25/2017
63
5’ Adenosine Monophosphate-activated Protein Kinase Activators
• Response to oxidative stress- Activated AMPK phosphorylates its main downstream targets of lipid homeostasis• ACETYL-COA carboxylase and hydroxymethylglutaryl CoA reductase.
These are primarily involved in the rate-limiting steps• Promote fatty acid oxidation
• Adaptive responses for cell survival• Fortify cellular autophagy, antioxidant defense and mitochondrial bio-
genesis
1/25/2017
64
5’ Adenosine Monophosphate-activated Protein Kinase Activators
• Sirtuin 1 (Sirt1) protein• founding member of a family of NAD+-dependent deacetylases and is
linked to longevity associated with calorie reduction• Expression and activity significantly reduced in type 2 diabetic animal
models and human kidneys the
• Mechanism of Sirt1 reduction in the diabetic condition has not been clarified, • Recent publications showed - AMPK activation by resveratrol and
theobromine leads to Sirt1 activation, which protects the diabetic kidney
1/25/2017
65
5’ Adenosine Monophosphate-activated Protein Kinase Activators
• Conventional activators of AMPK providing additional renoprotective effects in addition to their intrinsic activities –• 5-aminoimidazole-4-carboxamide ribonucleoside, • Metformin, • Adiponectin, and • Resveratrol
1/25/2017
66
Endothelin Receptor Antagonist
• Avosentan on Time to Doubling of Serum Creatinine, End Stage Renal Disease or Death in Patients With Type 2 Diabetes Mel-litus and Diabetic Nephropathy (ASCEND) trial• Favorable effect of reducing albuminuria when added to standard
treatment
• Terminated due to-• An increased risk of fluid overload and consequent congestive heart
failure resulting from proximal tubular sodium reabsorption
1/25/2017
68
Endothelin Receptor Antagonist
• Ongoing Study of Diabetic Nephropathy With Atrasentan(SONAR) phase III trial • Approaching its closing date, though some safety issues concerning
edema and heart disease are constantly being raised
1/25/2017
69
Antioxidative and Anti-inflammatory Agent
• Bardoxolone• Powerful antioxidative and anti-inflammatory effects through the
activation of the nuclear 1 factor-related factor 2 transcription factor• Failed to produce promising results
• Dropped from BEAM and BEACON trials, • Trivial muscle cramps to serious issues including heart failure, • Non-fatal myocardial infarction, stroke, and cardiovascular mortality• Also increased urine albumin excretion and blood pressure
1/25/2017
70
Glycosaminoglycans
• Sulodexide
• Potentiates the antiprotease activities of both antithrombin III and heparin cofactor II, shown • Beneficial effects in diabetic animal models• Failed to prove efficacious in the sulodexide macroalbuminuria (Sun-
MACRO) trial
1/25/2017
71
Others
• Xanthine oxidase inhibitors• Proven efficacy in terms of delaying the decline in the rate of eGFR in a
relatively small sample of CKD patients • Need to be validated in a larger population
• Anti-transforming growth factor β (TGF-β) antibody (LY2382770),• Effect demonstrated in an animal model, has not yet been translated into
human data
1/25/2017
72
Others
• Pentoxifylline- methylxanthine derivative and nonspecific PDI• Effects anti-inflammatory, antiproliferative, and ant-fibrotic actions
• Pentoxifylline for Renoprotection in Diabetic Nephropathy (PREDIAN) trial, • Rate of eGFR decline and the change in urinary albumin excretion were
significantly lower
• Stem cell therapy in experimental DN models has not yet shown efficacy in either diabetic mice or rat models
1/25/2017
73
Points to Remember
• Diabetes is the leading cause of chronic kidney disease (CKD)
• Screened regularly for kidney disease• key markers- glomerular filtration rate (eGFR) and urine albumin
• Intensive management of blood glucose has shown great promise for people with diabetes, especially for those in the early stages of CKD.
1/25/2017
74
Points to Remember
• Agents proven blood pressure lowering and slowing the progression of kidney disease • Angiotensin-converting enzyme (ACE) inhibitors and • Angiotensin receptor blockers (ARBs)
• ACEi and ARBs dual blockade is not recommended
• In people with diabetes, excessive consumption of protein may be harmful.
1/25/2017
75